JAK inhibitor shows promise for type 1 diabetes in Aussie trial
Baricitinib appeared to limit the destruction of pancreatic beta cells, authors say.
The rheumatoid arthritis drug baricitinib may be a potent foe against type 1 diabetes, according to results from a world-first clinical trial.
Australian researchers report that daily baricitinib, a Janus kinase (JAK) inhibitor, for 48 weeks can help preserve beta cell function and reduce the need for exogenous insulin in patients newly diagnosed with type 1 diabetes.
